The goal of this research proposal is to unravel the role of RUNX2 in the biology of a very poor prognostic subtype of human leukemia, ie. early T-cell progenitor (ETP) ALL. Given that these ETP-ALL patients completely fail current chemotherapy treatment, this project addresses the urgent need to identify new drugable targets for therapeutic intervention in this aggressive haematological malignancy.